Importantly, targeting MPO with the potent irreversible inhibitor, 4‐aminobenzoic acid hydrazide (4‐ABAH), significantly reduced MM tumour burden in the 5TGM1‐KaLwRij mouse model of MM. Here, MPO is linked to Miyoshi myopathy.